All In Biotech

Drug Trial Radar · NCT06908304

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC

Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

Jul 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Maia BiotechnologyIndustry
Sponsor type
Industry
First posted
Apr 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.

Conditions

  • Carcinoma, Non-Small -Cell Lung

Interventions

  • 6-Thio-2'-DeoxyguanosineDrug

    small molecule telomere targeting agent

  • CemiplimabDrug

    programmed cell death protein 1 (PD-1) inhibitor

  • DocetaxelDrug

    Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.

  • VinorelbineDrug

    Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.

  • Gemcitabine aloneDrug

    Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Within 2 Years

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Centrum Medyczne Pratia

    Poznan, Poland · Recruiting

  • Oncolab S.R.L.

    Craiova, Romania · Recruiting

  • Spitalul Clinic Municipal de Urgenta Timisoara/ Clinica de Oncologie Medicala

    Timișoara, Romania · Recruiting

  • Changhua Christian Hospital (CCH)

    Changhua, Taiwan · Recruiting

  • Taipei Tzu Chi Hospital

    Chiayi City, Taiwan · Recruiting

  • Chang-Gung Memorial Hospital - KaoHsiung

    Kaohsiung City, Taiwan · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)

    Kaohsiung City, Taiwan · Recruiting

  • Chung Shan Medical University Hospital (CSMUH)

    Taichung, Taiwan · Recruiting

  • Taipei Medical University Hospital (TMUH)

    Taipei, Taiwan · Recruiting

  • Tri-Service General Hospital

    Taipei, Taiwan · Recruiting

  • Chang-Gung Memorial Hospital - Linko

    Taoyuan City, Taiwan · Recruiting

  • Medicalpark Hastanesi

    Adana, Turkey (Türkiye) · Recruiting

  • Liv Hospital

    Ankara, Turkey (Türkiye) · Recruiting

  • Göztepe Süleyman Yalçın Şehir Hastanesi

    Istanbul, Turkey (Türkiye) · Recruiting

  • İstinye University

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.